Even the popular press is excited about recent developments involving anti-CD3, a potential type 1 therapy with strong ties to UCSF. In a recent issue of FORBES Magazine, senior editor Robert Langreth reveals the long history of anti-CD3 -- a monoclonal antibody that stops beta cell destruction.
In late 2007, history was made when two pharmaceutical companies entered into global alliances to develop and commercialize anti-CD3 drug therapies to treat and potentially to prevent type 1diabetes: Eli Lilly and MacroGenics are developing teplizumab, and GlaxoSmithKline and Tolerx are developing otelixizumab. Of special significance – anti-CD3 may be the first exclusively type 1 diabetes treatment to progress this far in drug development.
Please see the following link for the original article.